Stuivenberg Gerrit A, Poon Annabel, Burton Jeremy P, Spence J David
Microbiology and Immunology, Western University, London N6A 3K7, Canada.
The Canadian Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, London N6A 4V2, Canada.
Microbiome Res Rep. 2024 Dec 21;4(1):11. doi: 10.20517/mrr.2024.22. eCollection 2025.
The rising global incidence of atherosclerosis highlights the inadequacies in our understanding of the pathophysiology and treatment of the disease. Increasing evidence outlines the importance of the intestinal microbiome in atherosclerosis, wherein gut-derived uremic toxins (GDUTs) may be of concern. Plasma levels of the GDUTs trimethylamine n-oxide (TMAO), -cresyl sulfate, and indoxyl sulfate are associated with accelerated renal function decline and increased cardiovascular risk. Thus, reducing the amount of GDUTs in circulation is expected to benefit patients with atherosclerosis. Because some beneficial bacteria can clear GDUTs and , orally administered probiotics targeting the intestinal tract represent a promising way to bring about these changes. Atherosclerosis such, this perspective reviews the potential use of probiotics to treat atherosclerosis, particularly in patients with non-traditional risk factors and/or impaired renal function.
全球动脉粥样硬化发病率的上升凸显了我们对该疾病病理生理学和治疗方法理解的不足。越来越多的证据表明肠道微生物群在动脉粥样硬化中具有重要作用，其中肠道源性尿毒症毒素（GDUTs）可能值得关注。血浆中GDUTs氧化三甲胺（TMAO）、对甲酚硫酸盐和吲哚硫酸盐的水平与肾功能加速下降及心血管风险增加相关。因此，减少循环中GDUTs的量有望使动脉粥样硬化患者受益。由于一些有益细菌可以清除GDUTs，口服针对肠道的益生菌是实现这些改变的一种有前景的方法。鉴于动脉粥样硬化，本综述探讨了益生菌治疗动脉粥样硬化的潜在用途，特别是在具有非传统风险因素和/或肾功能受损的患者中。
